4-Methoxy Chalcone

4-Methoxy Chalcone

SCHEMBL1566431

COc1ccc(/C=C/C(=O)c2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 1.00
CYP3A4 P08684 1/20 1.00
NFKB1 P19838 1/20 1.00
NFKB2 Q00653 1/20 1.00
RELA Q04206 1/20 1.00
MAOB P27338 8/20 0.88
MAPT P10636 5/20 0.88
KMT2A Q03164 3/20 0.88
MEN1 O00255 2/20 0.88
ALDH1A1 P00352 2/20 0.88
CYP1B1 Q16678 2/20 0.88
HSPD1 P10809 1/20 0.88
TNFRSF1A P19438 1/20 0.88
HSPE1 P61604 1/20 0.88
F3 P13726 2/20 0.84
XDH P47989 2/20 0.79
MAOA P21397 3/20 0.74
RAB9A P51151 2/20 0.74
P4HB P07237 1/20 0.74
CALM1 P0DP23 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
4-Methoxy Chalcone SCHEMBL521906 1.00 BCHE (1.00) BCHECYP3A4NFKB1NFKB2RELA
4-Methoxy Chalcone SCHEMBL9338705 1.00 BCHE (1.00) BCHECYP3A4NFKB1NFKB2RELA
SCHEMBL27977337 0.95 BCHE (0.91) BCHECYP3A4NFKB1NFKB2RELA
SCHEMBL10017455 0.95 BCHE (0.91) BCHECYP3A4NFKB1NFKB2RELA
4'-Methoxychalcone SCHEMBL3698831 0.95 MAOB (0.97) BCHECYP3A4NFKB1NFKB2RELA
4'-Methoxychalcone SCHEMBL3698834 0.95 MAOB (0.97) BCHECYP3A4NFKB1NFKB2RELA
SCHEMBL18972861 0.94 BCHE (0.88) BCHECYP3A4NFKB1NFKB2RELA
4'-Methoxychalcone SCHEMBL1675978 0.93 MAOB (1.00) BCHECYP3A4NFKB1NFKB2RELA
4'-Methoxychalcone SCHEMBL521905 0.93 MAOB (1.00) BCHECYP3A4NFKB1NFKB2RELA
4,4'-Dimethoxychalcone SCHEMBL978243 0.91 F3 (1.00) BCHECYP3A4NFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117384199-A Preparation of novel organic aluminum hydrogen compound and preparation method of unsaturated alcohol compound catalyzed by novel organic aluminum hydrogen compound 北京理工大学 2024-01-12 CN claimed
CN-113620901-B Crown ether derived chiral 1,1 '-bi-2, 2' -naphthol, preparation method and application thereof 杭州师范大学 2023-02-10 CN claimed
CN-115141621-A Oil-based fracturing fluid, multi-stage fracturing method and method for online monitoring productivity of reservoir intervals 中国石油化工股份有限公司 2022-10-04 CN claimed
US-20220003753-A1 METABOLIC PROFILING FOR THE DIAGNOSIS OF A SUBSET OF IDIOPATHIC AUTISM SPECTRUM DISORDER PATIENTS, ADS PHENOTYPE 1 STALICLA SA (CH) 2022-01-06 US claimed
US-20210401728-A1 Topical Compositions and Methods to Promote Optimal Dermal White Adipose Tissue Composition in Vivo GALANIN IVAN (US) 2021-12-30 US claimed
EP-3877540-A1 METABOLIC PROFILING FOR THE DIAGNOSIS OF A SUBSET OF IDIOPATHIC AUTISM SPECTRUM DISORDER PATIENTS, ASD PHENOTYPE 1 Stalicla S.A. (CH) 2021-09-15 EP claimed
CN-113260423-A Topical application composition and method for promoting optimal skin white adipose tissue composition in vivo 伊万·加拉宁 2021-08-13 CN claimed
CN-113166811-A Metabolic profiling for diagnosing subtype ASD phenotype 1 in patients with idiopathic autism spectrum disorders 斯大利卡拉公司 2021-07-23 CN claimed
US-11040117-B2 Treatment of a subtype of ASD Stalicla S.A. (CH) 2021-06-22 US claimed
US-20210169993-A1 TREATMENT OF A SUBTYPE OF ASD STALICLA SA (CH) 2021-06-10 US claimed
EP-3706807-A1 TREATMENT OF A SUBTYPE OF ASD Stalicla S.A. (CH) 2020-09-16 EP claimed
US-20190134152-A1 TREATMENT OF A SUBTYPE OF ASD Stalicla S.A. (CH) 2019-05-09 US claimed
EP-1450777-B1 PHARMACEUTICAL COMPOSITION CONTAINING CHALCONE OR ITS DERIVATIVES FOR MATRIX METALLOPROTEINASE INHIBITORY ACTIVITY ANGIOLAB INC (KR) 2013-05-08 EP claimed
US-7572831-B2 Composition containing chalcone ANGIOLAB, INC. (KR) 2009-08-11 US claimed
US-20040209952-A1 Composition containing chalcone ANGIOLAB, INC. (KR) 2004-10-21 US claimed
EP-1450777-A1 PHARMACEUTICAL COMPOSITION CONTAINING CHALCONE OR ITS DERIVATIVES FOR MATRIX METALLOPROTEINASE INHIBITORY ACTIVITY Angiolab Inc. (KR) 2004-09-01 EP claimed
WO-2003037315-A1 PHARMACEUTICAL COMPOSITION CONTAINING CHALCONE OR ITS DERIVATIVES FOR MATRIX METALLOPROTEINASE INHIBITORY ACTIVITY ANGIOLAB INC. (KR) 2003-05-08 WO claimed
JP-4202126-A None JP disclosed
US-4067823-A Thallium(III) reagents supported on montmorillonite clay minerals and oxythallation processes for utilizing same EMERY INDUSTRIES, INC. (US) 1978-01-10 US disclosed
US-3983288-A Fibers and fabrics containing optical brightening agents EASTMAN KODAK COMPANY (US) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209952-A1 Composition containing chalcone MMP25, MMP13, MMP17 BCHE 501/4885CYP3A4 1458/4885NFKB1 1407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.